Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.

The last article in this 5-part series provides a final overview of consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. Optimal management of rosacea requires careful assessment of the patient's clinical features with integration of therapies that adequately treat the presenting signs and symptoms. The treatment consensus recommendations from the AARS are based on 2 major common clinical presentations of rosacea: (1) centrofacial erythema with papulopustular lesions, and (2) centrofacial erythema without papulopustular lesions. The recommendations provided here serve to guide clinicians in their clinical practice.

[1]  Z. Fedorowicz,et al.  Interventions for rosacea. , 2015, Cochrane Database of Systematic Reviews.

[2]  D. Thiboutot,et al.  Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices. , 2014, Cutis.

[3]  D. Thiboutot,et al.  Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. , 2014, Cutis.

[4]  D. Thiboutot,et al.  Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. , 2013, Cutis.

[5]  D. Thiboutot,et al.  Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. , 2013, Cutis.

[6]  R. Gallo,et al.  Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. , 2013, Journal of the American Academy of Dermatology.

[7]  J. D. Del Rosso.  Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy? , 2013, Journal of the American Academy of Dermatology.

[8]  M. Steinhoff,et al.  Once‐daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies , 2012, The British journal of dermatology.

[9]  R. Gallo,et al.  Doxycycline Indirectly Inhibits Proteolytic Activation of Tryptic Kallikrein-Related Peptidases and Activation of Cathelicidin , 2012, The Journal of investigative dermatology.

[10]  H. Echizen,et al.  Clinically Significant Drug Interactions with Antacids , 2011, Drugs.

[11]  J. D. Del Rosso,et al.  Optimal management of papulopustular rosacea: rationale for combination therapy. , 2012, Journal of drugs in dermatology : JDD.

[12]  J. D. Del Rosso.  Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. , 2012, The Journal of clinical and aesthetic dermatology.

[13]  J. D. Del Rosso.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. , 2012, The Journal of clinical and aesthetic dermatology.

[14]  T. Luger,et al.  Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. , 2011, The journal of investigative dermatology. Symposium proceedings.

[15]  T. Rosen.  Antibiotic resistance: an editorial review with recommendations. , 2011, Journal of drugs in dermatology : JDD.

[16]  A. Fleischer.  Inflammation in rosacea and acne: Implications for patient care. , 2011, Journal of drugs in dermatology : JDD.

[17]  A. Menter,et al.  Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. , 2010, Journal of drugs in dermatology : JDD.

[18]  B. Elewski,et al.  Rosacea: a review of current topical, systemic and light-based therapies. , 2009, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[19]  R. Gallo,et al.  The molecular pathology of rosacea. , 2009, Journal of dermatological science.

[20]  M. Macsai,et al.  Standard management options for rosacea, part 2: options according to subtype. , 2009, Cutis.

[21]  A. Fleischer,et al.  A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. , 2009, Journal of drugs in dermatology : JDD.

[22]  J. D. Del Rosso.  Oral antibiotic drug interactions of clinical significance to dermatologists. , 2009, Dermatologic clinics.

[23]  G. Webster,et al.  American Acne & Rosacea Society rosacea medical management guidelines. , 2008, Journal of drugs in dermatology : JDD.

[24]  J. D. Del Rosso,et al.  Comprehensive medical management of rosacea: an interim study report and literature review. , 2008, The Journal of clinical and aesthetic dermatology.

[25]  W. Giannobile,et al.  Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. , 2008, Journal of periodontology.

[26]  J. Leyden,et al.  Status report on antibiotic resistance: implications for the dermatologist. , 2007, Dermatologic clinics.

[27]  J. Leyden,et al.  Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. , 2007, Cutis.

[28]  M. Liang,et al.  Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. , 2004, Journal of the American Academy of Dermatology.

[29]  G. Krueger,et al.  Topical metronidazole maintains remissions of rosacea. , 1998, Archives of dermatology.